| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 74 | 2020 | 256 | 9.030 |
Why?
|
| Hyperthermia, Induced | 68 | 2020 | 236 | 8.130 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 47 | 2020 | 154 | 4.810 |
Why?
|
| Appendiceal Neoplasms | 29 | 2020 | 99 | 4.510 |
Why?
|
| Liver Neoplasms | 18 | 2018 | 164 | 4.250 |
Why?
|
| Colorectal Neoplasms | 23 | 2020 | 220 | 4.100 |
Why?
|
| Pancreatic Neoplasms | 12 | 2020 | 131 | 4.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2021 | 442 | 4.040 |
Why?
|
| Hepatectomy | 20 | 2018 | 57 | 3.620 |
Why?
|
| Gallbladder Neoplasms | 22 | 2021 | 35 | 3.080 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2020 | 373 | 3.040 |
Why?
|
| Bile Duct Neoplasms | 21 | 2019 | 33 | 3.010 |
Why?
|
| Combined Modality Therapy | 64 | 2020 | 551 | 2.860 |
Why?
|
| Adenocarcinoma | 19 | 2019 | 298 | 2.770 |
Why?
|
| Survival Rate | 72 | 2021 | 892 | 2.440 |
Why?
|
| Chemotherapy, Adjuvant | 26 | 2021 | 185 | 2.000 |
Why?
|
| Prognosis | 59 | 2021 | 1529 | 1.970 |
Why?
|
| Middle Aged | 128 | 2021 | 11838 | 1.860 |
Why?
|
| Pancreaticoduodenectomy | 9 | 2020 | 23 | 1.860 |
Why?
|
| Retrospective Studies | 73 | 2021 | 3609 | 1.790 |
Why?
|
| Humans | 189 | 2021 | 32271 | 1.790 |
Why?
|
| Aged | 114 | 2021 | 10249 | 1.750 |
Why?
|
| Carcinoma | 17 | 2017 | 92 | 1.690 |
Why?
|
| Female | 143 | 2021 | 19943 | 1.670 |
Why?
|
| Antineoplastic Agents | 21 | 2020 | 595 | 1.570 |
Why?
|
| Male | 130 | 2021 | 19437 | 1.540 |
Why?
|
| Surgical Wound Infection | 5 | 2019 | 98 | 1.520 |
Why?
|
| Follow-Up Studies | 49 | 2021 | 2238 | 1.510 |
Why?
|
| Neoplasm Staging | 48 | 2020 | 458 | 1.470 |
Why?
|
| Negative-Pressure Wound Therapy | 3 | 2019 | 38 | 1.420 |
Why?
|
| Pancreatectomy | 5 | 2019 | 25 | 1.370 |
Why?
|
| Mitomycin | 17 | 2020 | 50 | 1.340 |
Why?
|
| Treatment Outcome | 52 | 2020 | 3408 | 1.320 |
Why?
|
| Postoperative Complications | 17 | 2020 | 818 | 1.250 |
Why?
|
| Colonic Neoplasms | 12 | 2016 | 70 | 1.140 |
Why?
|
| Biliary Tract Neoplasms | 5 | 2018 | 10 | 1.130 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 19 | 1.130 |
Why?
|
| Adult | 74 | 2020 | 9260 | 1.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 22 | 2019 | 71 | 0.970 |
Why?
|
| Cholangiocarcinoma | 7 | 2019 | 12 | 0.930 |
Why?
|
| Vascular Surgical Procedures | 4 | 2017 | 85 | 0.930 |
Why?
|
| Aged, 80 and over | 46 | 2019 | 3893 | 0.910 |
Why?
|
| Laparoscopy | 4 | 2019 | 184 | 0.900 |
Why?
|
| Adenocarcinoma, Mucinous | 7 | 2020 | 28 | 0.900 |
Why?
|
| Lymphatic Metastasis | 31 | 2018 | 168 | 0.860 |
Why?
|
| Melanoma | 9 | 2019 | 166 | 0.830 |
Why?
|
| Prospective Studies | 36 | 2020 | 2315 | 0.820 |
Why?
|
| Skin Neoplasms | 10 | 2019 | 220 | 0.790 |
Why?
|
| Medical Oncology | 3 | 2019 | 90 | 0.780 |
Why?
|
| Lymph Nodes | 11 | 2020 | 113 | 0.780 |
Why?
|
| Biliary Tract Surgical Procedures | 3 | 2017 | 7 | 0.730 |
Why?
|
| Neoplasms | 9 | 2020 | 763 | 0.730 |
Why?
|
| Antibiotics, Antineoplastic | 7 | 2007 | 69 | 0.720 |
Why?
|
| Pancreatic Fistula | 1 | 2020 | 4 | 0.650 |
Why?
|
| Laparotomy | 4 | 2017 | 30 | 0.640 |
Why?
|
| Infusions, Parenteral | 17 | 2016 | 63 | 0.630 |
Why?
|
| Mesothelioma | 6 | 2019 | 33 | 0.630 |
Why?
|
| Case Management | 1 | 2019 | 6 | 0.620 |
Why?
|
| Risk Assessment | 11 | 2017 | 1423 | 0.600 |
Why?
|
| Bile Ducts | 2 | 2018 | 19 | 0.590 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2019 | 12 | 0.590 |
Why?
|
| Vascular Fistula | 1 | 2019 | 4 | 0.580 |
Why?
|
| Seroma | 1 | 2019 | 5 | 0.580 |
Why?
|
| Electroporation | 1 | 2019 | 15 | 0.580 |
Why?
|
| Intestinal Fistula | 1 | 2019 | 9 | 0.580 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 772 | 0.580 |
Why?
|
| Ablation Techniques | 1 | 2019 | 24 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 395 | 0.580 |
Why?
|
| United States | 22 | 2020 | 4069 | 0.560 |
Why?
|
| Vascular Neoplasms | 2 | 2010 | 12 | 0.560 |
Why?
|
| Leiomyosarcoma | 2 | 2010 | 10 | 0.550 |
Why?
|
| Quality of Life | 11 | 2020 | 969 | 0.550 |
Why?
|
| Vena Cava, Inferior | 2 | 2010 | 28 | 0.550 |
Why?
|
| Neoplasm Invasiveness | 10 | 2017 | 180 | 0.530 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 24 | 0.530 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 322 | 0.530 |
Why?
|
| Travel | 1 | 2017 | 14 | 0.530 |
Why?
|
| Blood Vessels | 3 | 2017 | 57 | 0.510 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 3 | 0.510 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2017 | 18 | 0.500 |
Why?
|
| Young Adult | 18 | 2020 | 2651 | 0.500 |
Why?
|
| Breast Neoplasms | 12 | 2013 | 764 | 0.490 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 48 | 0.480 |
Why?
|
| Choledochal Cyst | 1 | 2015 | 6 | 0.450 |
Why?
|
| Abdominal Neoplasms | 4 | 2014 | 13 | 0.450 |
Why?
|
| Time Factors | 16 | 2018 | 2203 | 0.430 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 198 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 38 | 0.420 |
Why?
|
| Thalidomide | 1 | 2014 | 32 | 0.420 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 650 | 0.420 |
Why?
|
| Peritoneum | 6 | 2020 | 32 | 0.400 |
Why?
|
| Databases, Factual | 12 | 2020 | 367 | 0.400 |
Why?
|
| Blood Transfusion | 4 | 2019 | 69 | 0.390 |
Why?
|
| Cholecystectomy | 6 | 2020 | 21 | 0.390 |
Why?
|
| Neoplasm Metastasis | 8 | 2016 | 221 | 0.390 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 104 | 0.390 |
Why?
|
| Survival Analysis | 10 | 2016 | 476 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 904 | 0.360 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2017 | 35 | 0.360 |
Why?
|
| Risk Factors | 14 | 2018 | 3933 | 0.360 |
Why?
|
| Portal Vein | 2 | 2017 | 27 | 0.330 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2010 | 52 | 0.310 |
Why?
|
| Stomach Neoplasms | 5 | 2016 | 113 | 0.310 |
Why?
|
| Adolescent | 14 | 2017 | 3516 | 0.310 |
Why?
|
| Length of Stay | 7 | 2018 | 321 | 0.310 |
Why?
|
| Neoplasm, Residual | 8 | 2018 | 22 | 0.300 |
Why?
|
| Predictive Value of Tests | 13 | 2019 | 880 | 0.290 |
Why?
|
| Catheter Ablation | 4 | 2005 | 113 | 0.280 |
Why?
|
| Reoperation | 7 | 2017 | 247 | 0.280 |
Why?
|
| Patient Selection | 5 | 2021 | 272 | 0.280 |
Why?
|
| Biopsy | 1 | 2009 | 249 | 0.270 |
Why?
|
| Incidence | 5 | 2018 | 1242 | 0.270 |
Why?
|
| Common Bile Duct | 3 | 2020 | 6 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 5 | 2016 | 62 | 0.270 |
Why?
|
| Preoperative Care | 4 | 2017 | 125 | 0.270 |
Why?
|
| Microwaves | 1 | 2007 | 8 | 0.260 |
Why?
|
| Electrocoagulation | 1 | 2007 | 11 | 0.260 |
Why?
|
| Pseudomyxoma Peritonei | 3 | 2013 | 13 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2016 | 19 | 0.250 |
Why?
|
| Gene Expression | 1 | 2008 | 346 | 0.250 |
Why?
|
| Organoplatinum Compounds | 5 | 2016 | 41 | 0.240 |
Why?
|
| Morbidity | 7 | 2017 | 98 | 0.230 |
Why?
|
| Logistic Models | 3 | 2017 | 743 | 0.220 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 27 | 0.220 |
Why?
|
| Abdominal Wall | 1 | 2004 | 24 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 83 | 0.210 |
Why?
|
| Lymph Node Excision | 9 | 2020 | 94 | 0.210 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 315 | 0.200 |
Why?
|
| Hepatic Veins | 1 | 2003 | 3 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 84 | 0.200 |
Why?
|
| Sarcoma | 2 | 2014 | 82 | 0.190 |
Why?
|
| Cohort Studies | 9 | 2020 | 1839 | 0.190 |
Why?
|
| Coloring Agents | 5 | 2009 | 32 | 0.190 |
Why?
|
| Registries | 2 | 2017 | 294 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2010 | 170 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2002 | 25 | 0.180 |
Why?
|
| Liver | 2 | 2014 | 492 | 0.180 |
Why?
|
| Radiopharmaceuticals | 5 | 2010 | 95 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 312 | 0.170 |
Why?
|
| Incidental Findings | 5 | 2021 | 25 | 0.170 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2018 | 6 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 72 | 0.160 |
Why?
|
| Rosaniline Dyes | 7 | 2009 | 19 | 0.160 |
Why?
|
| Drainage | 2 | 2017 | 65 | 0.160 |
Why?
|
| CA-19-9 Antigen | 2 | 2017 | 7 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 245 | 0.160 |
Why?
|
| Risk | 2 | 2020 | 305 | 0.160 |
Why?
|
| Depression | 4 | 2020 | 427 | 0.160 |
Why?
|
| Ileal Neoplasms | 2 | 2013 | 4 | 0.160 |
Why?
|
| Jejunal Neoplasms | 2 | 2013 | 6 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2017 | 69 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2020 | 187 | 0.150 |
Why?
|
| Carcinoma, Lobular | 3 | 2011 | 12 | 0.150 |
Why?
|
| Pancreatic Diseases | 1 | 2019 | 21 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 40 | 0.140 |
Why?
|
| Pain Measurement | 2 | 2017 | 339 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 114 | 0.140 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 335 | 0.140 |
Why?
|
| Neutrophils | 2 | 2016 | 120 | 0.140 |
Why?
|
| Intensive Care Units | 2 | 2015 | 121 | 0.130 |
Why?
|
| Hepatic Artery | 1 | 2017 | 14 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2019 | 229 | 0.130 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 287 | 0.130 |
Why?
|
| Endoscopy | 1 | 2017 | 54 | 0.130 |
Why?
|
| Sensitivity and Specificity | 10 | 2011 | 556 | 0.130 |
Why?
|
| Diaphragm | 2 | 2014 | 37 | 0.130 |
Why?
|
| Jaundice, Obstructive | 1 | 2017 | 2 | 0.130 |
Why?
|
| Communication Barriers | 1 | 2017 | 18 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 174 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 257 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2018 | 185 | 0.130 |
Why?
|
| Income | 1 | 2017 | 66 | 0.130 |
Why?
|
| Disease Progression | 3 | 2014 | 591 | 0.130 |
Why?
|
| Health Status | 5 | 2019 | 356 | 0.130 |
Why?
|
| Mastectomy | 4 | 2013 | 59 | 0.130 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 1 | 0.130 |
Why?
|
| Mastectomy, Segmental | 2 | 2010 | 25 | 0.130 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2017 | 21 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2017 | 25 | 0.130 |
Why?
|
| Splenectomy | 2 | 2014 | 22 | 0.130 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 10 | 0.120 |
Why?
|
| Intraoperative Period | 7 | 2018 | 43 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 62 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2016 | 56 | 0.120 |
Why?
|
| Nomograms | 1 | 2016 | 35 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 130 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2014 | 197 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 31 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 167 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 144 | 0.110 |
Why?
|
| Palliative Care | 1 | 2016 | 50 | 0.110 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 8 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 58 | 0.110 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 20 | 0.110 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.110 |
Why?
|
| Shock, Septic | 1 | 2015 | 26 | 0.110 |
Why?
|
| Patient Admission | 1 | 2015 | 54 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 50 | 0.110 |
Why?
|
| Rectal Neoplasms | 2 | 2013 | 19 | 0.110 |
Why?
|
| Bandages | 2 | 2013 | 34 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 854 | 0.110 |
Why?
|
| Intraoperative Care | 6 | 2015 | 52 | 0.110 |
Why?
|
| Ileal Diseases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Vomiting | 1 | 2014 | 20 | 0.110 |
Why?
|
| Cholelithiasis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Hernia, Abdominal | 1 | 2014 | 9 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 38 | 0.110 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 12 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2014 | 85 | 0.110 |
Why?
|
| Nausea | 1 | 2014 | 50 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2015 | 455 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2014 | 33 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 46 | 0.100 |
Why?
|
| Appendix | 1 | 2014 | 6 | 0.100 |
Why?
|
| Cytological Techniques | 2 | 2011 | 17 | 0.100 |
Why?
|
| Ascites | 1 | 2013 | 13 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2013 | 31 | 0.100 |
Why?
|
| Wound Healing | 2 | 2013 | 184 | 0.100 |
Why?
|
| Urologic Diseases | 1 | 2013 | 35 | 0.100 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 7 | 0.100 |
Why?
|
| Consensus | 1 | 2013 | 87 | 0.100 |
Why?
|
| Taxoids | 1 | 2013 | 50 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 50 | 0.090 |
Why?
|
| Cisplatin | 4 | 2014 | 77 | 0.090 |
Why?
|
| Anthracyclines | 1 | 2013 | 52 | 0.090 |
Why?
|
| Child | 7 | 2014 | 2431 | 0.090 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2009 | 5 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 160 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 390 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2009 | 19 | 0.090 |
Why?
|
| Feasibility Studies | 4 | 2016 | 309 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2016 | 62 | 0.080 |
Why?
|
| Decision Making | 1 | 2012 | 190 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 9 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2009 | 9 | 0.070 |
Why?
|
| Mammaplasty | 1 | 2009 | 26 | 0.070 |
Why?
|
| Frozen Sections | 4 | 2018 | 19 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1076 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1211 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 23 | 0.070 |
Why?
|
| Carboplatin | 3 | 2013 | 42 | 0.070 |
Why?
|
| Perioperative Care | 2 | 2019 | 51 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2008 | 17 | 0.070 |
Why?
|
| ROC Curve | 2 | 2018 | 169 | 0.070 |
Why?
|
| Perfusion | 2 | 2020 | 75 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 60 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 27 | 0.060 |
Why?
|
| Nevus | 2 | 2004 | 17 | 0.060 |
Why?
|
| Lymphatic Vessels | 2 | 2017 | 7 | 0.060 |
Why?
|
| Necrosis | 1 | 2007 | 53 | 0.060 |
Why?
|
| Cell Death | 1 | 2007 | 79 | 0.060 |
Why?
|
| Mental Health | 2 | 2019 | 111 | 0.060 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 8 | 0.060 |
Why?
|
| Equipment Design | 1 | 2007 | 178 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 93 | 0.060 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2006 | 3 | 0.060 |
Why?
|
| Hemoperitoneum | 1 | 2006 | 4 | 0.060 |
Why?
|
| African Americans | 1 | 2013 | 1335 | 0.060 |
Why?
|
| Animals | 3 | 2008 | 8196 | 0.060 |
Why?
|
| Activities of Daily Living | 4 | 2011 | 246 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Probability | 2 | 2016 | 155 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1111 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 52 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 161 | 0.060 |
Why?
|
| Endosonography | 1 | 2006 | 55 | 0.060 |
Why?
|
| Colectomy | 3 | 2014 | 30 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 137 | 0.060 |
Why?
|
| Quality of Health Care | 2 | 2020 | 148 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 65 | 0.060 |
Why?
|
| North Carolina | 3 | 2015 | 1300 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 61 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2016 | 554 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 47 | 0.050 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 544 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 500 | 0.050 |
Why?
|
| Skin, Artificial | 1 | 2004 | 34 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 756 | 0.050 |
Why?
|
| Keratins | 3 | 2010 | 39 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2015 | 124 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 120 | 0.050 |
Why?
|
| Massage | 1 | 2003 | 8 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 55 | 0.050 |
Why?
|
| Breast | 1 | 2003 | 63 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 2014 | 45 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 422 | 0.050 |
Why?
|
| Swine | 1 | 2003 | 228 | 0.050 |
Why?
|
| Cytodiagnosis | 3 | 2011 | 15 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2003 | 79 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2004 | 240 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 128 | 0.050 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2014 | 10 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1480 | 0.040 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 72 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 129 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 99 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2016 | 863 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 28 | 0.030 |
Why?
|
| Data Collection | 1 | 2018 | 171 | 0.030 |
Why?
|
| Appendectomy | 1 | 2018 | 19 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 246 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 30 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 25 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 90 | 0.030 |
Why?
|
| Bilirubin | 1 | 2017 | 23 | 0.030 |
Why?
|
| Malpractice | 1 | 2017 | 20 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 59 | 0.030 |
Why?
|
| Fluorescent Dyes | 2 | 2007 | 52 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 25 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Leucovorin | 1 | 2016 | 19 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 45 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 39 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 135 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 35 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 79 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 55 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2016 | 79 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 129 | 0.030 |
Why?
|
| Peripheral Nerves | 1 | 2016 | 60 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 82 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 38 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 82 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 179 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 146 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 230 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 545 | 0.030 |
Why?
|
| Mammography | 2 | 2005 | 41 | 0.030 |
Why?
|
| Pneumonia | 1 | 2014 | 62 | 0.030 |
Why?
|
| Omentum | 1 | 2014 | 25 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 78 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 60 | 0.030 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 100 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 202 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2013 | 16 | 0.020 |
Why?
|
| Axilla | 2 | 2003 | 17 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 854 | 0.020 |
Why?
|
| International Agencies | 1 | 2012 | 10 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 59 | 0.020 |
Why?
|
| Sleep | 1 | 2012 | 87 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 21 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 292 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 57 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 702 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 63 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 622 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 42 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2009 | 70 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 19 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 62 | 0.020 |
Why?
|
| Neck | 1 | 2007 | 32 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 175 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 8 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2006 | 22 | 0.020 |
Why?
|
| Rupture | 1 | 2006 | 33 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1178 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 62 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 186 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 192 | 0.010 |
Why?
|
| Vacuum | 1 | 2004 | 23 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 2004 | 11 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 2004 | 23 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2004 | 20 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2004 | 40 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 273 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 37 | 0.010 |
Why?
|
| Face | 1 | 2003 | 29 | 0.010 |
Why?
|
| Cell Biology | 1 | 2002 | 2 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 229 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 31 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 40 | 0.010 |
Why?
|
| Cryopreservation | 1 | 2002 | 52 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 536 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 212 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 59 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1233 | 0.010 |
Why?
|